Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3100-3109

  Smith, Sonali M ^a   Burns, Linda J ^b   Inwards, David J ^c   Van Besien, Koen ^d   Wiernik, Peter H ^e   Cairo, Mitchell S ^f   Le Rademacher, Jennifer ^g   He, Wensheng ^g   Hari, Parameswaran N ^g   Fenske, Timothy S ^g   Suzuki, Ritsuro ^h   Hsu, Jack W ⁱ   Hale, Gregory A ^j   Maharaj, Dipnarine ^k   Schouten, Harry C ^l   Holmberg, Leona A ^m   Sureda, Anna ⁿ   Gale, Robert Peter ^o   Montoto, Silvia ^p   Freytes, Cesar O ^q   Maziarz, Richard Thomas ^r   Gross, Thomas G ^s   Lazarus, Hillard M ^t   Costa, Luciano J ^u   Laport, Ginna G ^v   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j All Children's Hospital   (United States)

^k South Florida Bone Marrow Stem Cell Transplant Institute   (United States)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^q UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^r OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^s NATIONWIDE CHILDREN S HOSPITAL   (United States)

^t UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^u MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^v STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOLOGY; HUMAN; LARGE CELL LYMPHOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE; UNRELATED DONORS; ADOLESCENT; AUTOTRANSPLANTATION; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84886463678     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.0188     Document Type: Article

References (22)

1. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
2. Schmitz N, Trumper L, Ziepert M, et al: Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116: 3418-3425, 2010.
3. Kyriakou C, Canals C, Goldstone A, et al: High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224, 2008.
4. Nademanee A, Palmer JM, Popplewell L, et al: High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): Analysis of prognostic factors. Biol Blood Marrow Transplant 17:1481-1489, 2011.
5. Reimer P, Rü diger T, Geissinger E, et al: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. J Clin Oncol 27:106- 113, 2009.
6. Rodríguez J, Conde E, Gutié rrez A, et al: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group. Eur J Haematol 79:32-38, 2007.
7. Bacigalupo A, Ballen K, Rizzo D, et al: Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 15:1628- 1633, 2009.
8. Weisdorf D, Spellman S, Haagenson M, et al: Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival. Biol Blood Marrow Transplant 14:748-758, 2008.
9. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
10. Chen AI, McMillan A, Negrin RS, et al: Longterm results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience. Biol Blood Marrow Transplant 14:741-747, 2008.
11. Feyler S, Prince HM, Pearce R, et al: The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplant 40:443-450, 2007.
12. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134:202-207, 2006.
13. Song KW, Mollee P, Keating A, et al: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological subtype. Br J Haematol 120:978-985, 2003.
14. Corradini P, Dodero A, Zallio F, et al: Graftversus- lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.
15. Delioukina M, Zain J, Palmer JM, et al: Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 47:65-72, 2012.
16. Dodero A, Spina F, Narni F, et al: Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: Long-term remissions and response to donor lymphocyte infusions support the role of a graft-versuslymphoma effect. Leukemia 26:520-526, 2012.
17. Zain J, Palmer JM, Delioukina M, et al: Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 52:1463-1473, 2011.
18. Le Gouill S, Milpied N, Buzyn A, et al: Graftversus- lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Socié té Française de Greffe de Moë lle et de Thé rapie Cellulaire. J Clin Oncol 26:2264-2271, 2008.
19. Jacobsen ED, Kim HT, Ho VT, et al: A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22:1608-1613, 2011.
20. Suzuki R, Kagami Y, Takeuchi K, et al: Prognostic significance of CD56 expression for ALKpositive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993- 3000, 2000.
21. Savage KJ, Harris NL, Vose JM, et al: ALKanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
22. Mercadal S, Briones J, Xicoy B, et al: Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958-963, 2008.